ArticleOncology letters2019
Scutellarein suppresses Aβ-induced memory impairment via inhibition of the NF-κB pathway
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- LC-ESI-QTOF-MS/MS Characterization of Phenolic Compounds in the Stem, Roots, and Leaves ofFood science & nutrition · 2025Article
- Therapeutic Role of Scutellarein in Neurological Disorders.Current pharmaceutical design · 2025Review
- Scutellarein Ameliorated Chondrocyte Inflammation and Osteoarthritis in Rats.Current medical science · 2024Article
- Current advances on the therapeutic potential of scutellarin: an updated review.Natural products and bioprospecting · 2024Review
- A Multilevel Study of Eupatorin and Scutellarein as Anti-Amyloid Agents in Alzheimer's Disease.Biomedicines · 2023Article
- Autophagy Induction byPharmaceuticals (Basel, Switzerland) · 2023Review
- Medicinal Herbs and Their Derived Ingredients Protect against Cognitive Decline in In Vivo Models of Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Review
- Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version.Frontiers in pharmacology · 2022Review
- Suan-Zao-Ren Decoction ameliorates synaptic plasticity through inhibition of the Aβ deposition and JAK2/STAT3 signaling pathway in AD model of APP/PS1 transgenic mice.Chinese medicine · 2021Article
- Flavonoids for treatment of Alzheimer's disease: An up to date review.EXCLI journal · 2021Article
- Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination.International journal of molecular medicine · 2020Article
- Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer's Disease.Frontiers in pharmacology · 2020Review
- Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis.Therapeutic advances in chronic disease · 2020Article
Corrections and comments
- Retraction · 2025-11-26Author Unresponsive · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · Plagiarism of Image ·
- Retracted
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The flavonoid compound scutellarin (Scu) is a traditional Chinese medicine used to treat a variety of diseases; however, the use of scutellarein (Scue), the hydrolysate of Scu, and its mechanisms of action in Alzheimer's disease (AD) have not been fully elucidated. In the present study, the effects of Scue on amyloid β (Aβ)-induced AD-like pathology were investigated. An
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.